Umoja Biopharma Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
195
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$100M
- Investors
-
24
Umoja Biopharma General Information
Description
Operator of a biotechnology platform designed to advance a novel approach to cancer immunotherapy by generating engineered immune cells. The company's platform offers integrated gene delivery technology, in-house lentiviral vector development, and a pipeline of in vivo cell therapies, enabling clinical researchers to pursue treatments that may reach more patients with improved accessibility and immune system-based control compared to conventional methods.
Contact Information
Website
www.umoja-biopharma.comCorporate Office
- 1150 Eastlake Avenue East
- Suite 400
- Seattle, WA 98109
- United States
Corporate Office
- 1150 Eastlake Avenue East
- Suite 400
- Seattle, WA 98109
- United States
Umoja Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 19-Jan-2025 | $100M | Completed | Pre-Clinical Trials | ||
| 3. Early Stage VC (Series B) | 15-Jun-2021 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 18-Nov-2020 | $53M | $61M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 21-Nov-2019 | $8M | $8M | Completed | Pre-Clinical Trials |
Umoja Biopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Series A | ||||||||
| Seed 1 | 565,996 | $0.000100 | $2.24 | $2.24 | 1x | $2 | 0.6% | |
| Seed | 2,400,773 | $0.000100 | $2.8 | $2.8 | 1x | $2.25 | 2.81% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Umoja Biopharma Comparisons
Industry
Financing
Details
Umoja Biopharma Competitors (63)
One of Umoja Biopharma’s 63 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Phio Pharmaceuticals | Formerly Accelerator/Incubator backed | King of Prussia, PA | ||||
| TME Pharma | Formerly VC-backed | Berlin, Germany | ||||
| Cellaion | Formerly VC-backed | Mont-Saint-Guibert, Belgium | ||||
| Xenetic Biosciences | Corporation | Framingham, MA |
Umoja Biopharma Patents
Umoja Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026143070-A1 | Improved rapamycin activated synthetic receptor transgene constructs | Pending | 23-Dec-2024 | ||
| WO-2026143065-A1 | Polynucleotide construct for chimeric antigen receptor expression and related viral vectors and methods | Pending | 23-Dec-2024 | ||
| WO-2026136737-A1 | Cd58-pseudotyped viral particles and uses thereof | Pending | 19-Dec-2024 | ||
| WO-2026123000-A2 | Cytokine armored engineered innate lymphoid cells and related methods | Pending | 06-Dec-2024 | ||
| WO-2026123000-A3 | Cytokine armored engineered innate lymphoid cells and related methods | Pending | 06-Dec-2024 | C12N5/0647 |
Umoja Biopharma Signals
Umoja Biopharma Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARK Ventures (US) | Venture Capital | Minority | ||
| Double Point Ventures | Venture Capital | Minority | ||
| K2 HealthVentures | Venture Capital | Minority | ||
| Myeloma Investment Fund | Not-For-Profit Venture Capital | Minority | ||
| Realm Capital Ventures | Venture Capital | Minority |
Umoja Biopharma FAQs
-
When was Umoja Biopharma founded?
Umoja Biopharma was founded in 2019.
-
Where is Umoja Biopharma headquartered?
Umoja Biopharma is headquartered in Seattle, WA.
-
What is the size of Umoja Biopharma?
Umoja Biopharma has 195 total employees.
-
What industry is Umoja Biopharma in?
Umoja Biopharma’s primary industry is Drug Discovery.
-
Is Umoja Biopharma a private or public company?
Umoja Biopharma is a Private company.
-
What is the current valuation of Umoja Biopharma?
The current valuation of Umoja Biopharma is .
-
What is Umoja Biopharma’s current revenue?
The current revenue for Umoja Biopharma is .
-
How much funding has Umoja Biopharma raised over time?
Umoja Biopharma has raised $371M.
-
Who are Umoja Biopharma’s investors?
ARK Ventures (US), Double Point Ventures, K2 HealthVentures, Myeloma Investment Fund, and Realm Capital Ventures are 5 of 24 investors who have invested in Umoja Biopharma.
-
Who are Umoja Biopharma’s competitors?
Adaptimmune Therapeutics, Phio Pharmaceuticals, TME Pharma, Cellaion, and Xenetic Biosciences are some of the 63 competitors of Umoja Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process